chrX-111708970-T-G
Position:
Variant summary
Our verdict is Benign. Variant got -9 ACMG points: 0P and 9B. BP6BS1BS2
The NM_001099922.3(ALG13):āc.756T>Gā(p.Phe252Leu) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000127 in 1,176,936 control chromosomes in the GnomAD database, with no homozygous occurrence. There are 5 hemizygotes in GnomAD. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Genomes: š 0.000063 ( 0 hom., 2 hem., cov: 23)
Exomes š: 0.0000075 ( 0 hom. 3 hem. )
Consequence
ALG13
NM_001099922.3 missense
NM_001099922.3 missense
Scores
1
4
12
Clinical Significance
Conservation
PhyloP100: 1.35
Genes affected
ALG13 (HGNC:30881): (ALG13 UDP-N-acetylglucosaminyltransferase subunit) The protein encoded by this gene is a subunit of a bipartite UDP-N-acetylglucosamine transferase. It heterodimerizes with asparagine-linked glycosylation 14 homolog to form a functional UDP-GlcNAc glycosyltransferase that catalyzes the second sugar addition of the highly conserved oligosaccharide precursor in endoplasmic reticulum N-linked glycosylation. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Dec 2009]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -9 ACMG points.
BP6
Variant X-111708970-T-G is Benign according to our data. Variant chrX-111708970-T-G is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 574279.We mark this variant Likely_benign, oryginal submissions are: {Likely_benign=1, Uncertain_significance=2}.
BS1
Variant frequency is greater than expected in population amr. gnomad4 allele frequency = 0.0000626 (7/111897) while in subpopulation AMR AF= 0.000568 (6/10565). AF 95% confidence interval is 0.000247. There are 0 homozygotes in gnomad4. There are 2 alleles in male gnomad4 subpopulation. Median coverage is 23. This position pass quality control queck.
BS2
High Hemizygotes in GnomAd4 at 2 XL gene
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
ALG13 | NM_001099922.3 | c.756T>G | p.Phe252Leu | missense_variant | 5/27 | ENST00000394780.8 | NP_001093392.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
ALG13 | ENST00000394780.8 | c.756T>G | p.Phe252Leu | missense_variant | 5/27 | 2 | NM_001099922.3 | ENSP00000378260 | A2 | |
ALG13-AS1 | ENST00000430794.1 | n.106+2026A>C | intron_variant, non_coding_transcript_variant | 5 |
Frequencies
GnomAD3 genomes AF: 0.0000626 AC: 7AN: 111897Hom.: 0 Cov.: 23 AF XY: 0.0000587 AC XY: 2AN XY: 34055
GnomAD3 genomes
AF:
AC:
7
AN:
111897
Hom.:
Cov.:
23
AF XY:
AC XY:
2
AN XY:
34055
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.00000685 AC: 1AN: 145969Hom.: 0 AF XY: 0.0000230 AC XY: 1AN XY: 43507
GnomAD3 exomes
AF:
AC:
1
AN:
145969
Hom.:
AF XY:
AC XY:
1
AN XY:
43507
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00000751 AC: 8AN: 1065039Hom.: 0 Cov.: 24 AF XY: 0.00000887 AC XY: 3AN XY: 338383
GnomAD4 exome
AF:
AC:
8
AN:
1065039
Hom.:
Cov.:
24
AF XY:
AC XY:
3
AN XY:
338383
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000626 AC: 7AN: 111897Hom.: 0 Cov.: 23 AF XY: 0.0000587 AC XY: 2AN XY: 34055
GnomAD4 genome
AF:
AC:
7
AN:
111897
Hom.:
Cov.:
23
AF XY:
AC XY:
2
AN XY:
34055
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:2Benign:1
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
Developmental and epileptic encephalopathy, 36 Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Oct 31, 2022 | This sequence change replaces phenylalanine, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 252 of the ALG13 protein (p.Phe252Leu). This variant is present in population databases (no rsID available, gnomAD 0.004%), including at least one homozygous and/or hemizygous individual. This variant has not been reported in the literature in individuals affected with ALG13-related conditions. ClinVar contains an entry for this variant (Variation ID: 574279). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt ALG13 protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. - |
Inborn genetic diseases Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Nov 01, 2016 | The p.F252L variant (also known as c.756T>G), located in coding exon 5 of the ALG13 gene, results from a T to G substitution at nucleotide position 756. The phenylalanine at codon 252 is replaced by leucine, an amino acid with highly similar properties. This variant was not reported in population based cohorts in the following databases: Database of Single Nucleotide Polymorphisms (dbSNP), NHLBI Exome Sequencing Project (ESP), and 1000 Genomes Project. In the ESP, this variant was not observed in 5147 samples with coverage at this position. This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. - |
not provided Benign:1
Likely benign, criteria provided, single submitter | clinical testing | GeneDx | Apr 28, 2021 | - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Benign
DANN
Uncertain
DEOGEN2
Benign
T;.;.;.;.
FATHMM_MKL
Uncertain
D
LIST_S2
Benign
T;T;.;T;.
M_CAP
Benign
T
MetaRNN
Uncertain
T;T;T;T;T
MetaSVM
Benign
T
MutationAssessor
Benign
L;.;.;.;.
MutationTaster
Benign
N;N
PrimateAI
Uncertain
T
PROVEAN
Benign
N;.;N;.;.
REVEL
Benign
Sift
Benign
T;.;T;.;.
Sift4G
Benign
T;T;T;T;T
Polyphen
D;D;D;D;D
Vest4
MutPred
Gain of catalytic residue at F252 (P = 0.0344);.;.;.;.;
MVP
MPC
ClinPred
D
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Varity_R
gMVP
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at